Captrust Financial Advisors Acquires 96,271 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Captrust Financial Advisors increased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 5.7% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,776,970 shares of the biopharmaceutical company's stock after purchasing an additional 96,271 shares during the period. Captrust Financial Advisors owned approximately 0.14% of Gilead Sciences worth $164,139,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Cary Street Partners Financial LLC bought a new position in shares of Gilead Sciences during the fourth quarter valued at about $586,000. Bayesian Capital Management LP bought a new position in Gilead Sciences during the 4th quarter worth approximately $1,995,000. Bellevue Group AG increased its stake in Gilead Sciences by 5.2% in the 4th quarter. Bellevue Group AG now owns 48,429 shares of the biopharmaceutical company's stock worth $4,473,000 after purchasing an additional 2,402 shares during the period. Bearing Point Capital LLC purchased a new stake in shares of Gilead Sciences during the fourth quarter valued at approximately $588,000. Finally, BLI Banque de Luxembourg Investments bought a new position in shares of Gilead Sciences in the fourth quarter worth approximately $2,302,000. Institutional investors own 83.67% of the company's stock.

Gilead Sciences Stock Up 0.4 %

GILD stock opened at $103.68 on Monday. The stock has a market capitalization of $129.10 billion, a P/E ratio of 280.22, a P/E/G ratio of 0.71 and a beta of 0.26. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $119.96. The business has a fifty day moving average price of $108.69 and a 200-day moving average price of $98.99.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.04. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The business had revenue of $6.67 billion for the quarter, compared to analysts' expectations of $6.77 billion. During the same quarter in the prior year, the business earned ($1.32) EPS. The business's revenue for the quarter was down .3% compared to the same quarter last year. Equities analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be paid a dividend of $0.79 per share. The ex-dividend date of this dividend is Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a yield of 3.05%. Gilead Sciences's dividend payout ratio is presently 66.53%.

Insider Activity

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction that occurred on Tuesday, April 15th. The shares were sold at an average price of $106.40, for a total value of $266,000.00. Following the transaction, the chief financial officer now owns 168,174 shares in the company, valued at $17,893,713.60. This represents a 1.46 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold 160,605 shares of company stock valued at $16,718,136 in the last ninety days. 0.27% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Oppenheimer cut their price target on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a report on Friday, April 25th. The Goldman Sachs Group boosted their price target on Gilead Sciences from $85.00 to $96.00 and gave the company a "neutral" rating in a report on Wednesday, February 12th. Deutsche Bank Aktiengesellschaft upgraded Gilead Sciences from a "hold" rating to a "buy" rating and lifted their price objective for the stock from $80.00 to $120.00 in a research report on Tuesday, February 18th. JPMorgan Chase & Co. raised their price target on Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research note on Thursday, March 27th. Finally, Cantor Fitzgerald began coverage on shares of Gilead Sciences in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 price objective on the stock. Nine analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $110.55.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.